Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 3/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | ULK1 | O75385 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12061562 | 0.99 | KIT (0.39) | KITHRH4CHRM2CHRM1CHRM3 | |
| SCHEMBL14308 | 0.78 | PARP1 (0.39) | KITHRH4CHRNA3ULK1TNKS | |
| SCHEMBL13994 | 0.76 | PARP1 (0.39) | KITHRH4CHRNA3ULK1TNKS | |
| SCHEMBL14027 | 0.74 | HRH4 (0.45) | KITHRH4ULK1 | |
| SCHEMBL12061561 | 0.72 | SLC6A4 (0.43) | CHRM1CHRM3 | |
| SCHEMBL17484485 | 0.72 | SLC6A4 (0.43) | CHRM1CHRM3 | |
| SCHEMBL13587 | 0.70 | DRD4 (0.35) | HRH4CHRM2CHRM1CHRM3CHRNA3 | |
| SCHEMBL13886 | 0.69 | ADORA2A (0.49) | KITHRH4TNKS | |
| SCHEMBL14077 | 0.67 | SLC6A4 (0.47) | CHRM1CHRM3 | |
| SCHEMBL14296 | 0.65 | KIT (0.35) | KITHRH4TNKSEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488525-B1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS INC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-9193731-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193731-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2011047319-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | KIT 3949/4885HRH4 3383/4885CHRM2 4820/4885 |
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | KIT 3949/4885HRH4 3383/4885CHRM2 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.